+1 (704) 266-3234

Global Anticoagulant Market 2017-2021

Published on: Feb 2017 | From USD $3500 | Published By: INFINITI RESEARCH | Number Of Pages: 79

ABSTRACT
About Anticoagulant Market
Anticoagulant prevent clot formations or the enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists; DTIs; and factor Xa inhibitors are among the anticoagulant that are available in the market. They are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction. Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, and Sanofi are some of the top vendors in the market.

Technavio’s analysts forecast the global anticoagulant market to grow at a CAGR of 7.42% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global anticoagulant market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders.

The market is divided into the following segments based on geography:
• Americas
• EMEA
• APAC

Technavio's report, Global Anticoagulant Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Bayer HealthCare
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Daiichi Sankyo
• Johnson & Johnson
• Sanofi

Other prominent vendors
• Abbott Vascular
• Abiomed
• AtriCure
• Biosensors International
• Biotronik
• BioVentrix
• C. R. Bard

Market driver
• Increasing demand for NOACs
• For a full, detailed list, view our report

Market challenge
• Increasing cost of NOACs
• For a full, detailed list, view our report

Market trend
• Strategic alliance
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents

PART 01: Executive summary 

PART 02: Scope of the report 


Market overview 
Top-vendor offerings 


PART 03: Market research methodology 


Research methodology 
Economic indicators 


PART 04: Introduction 


Key market highlights 


PART 05: Disease overview 

PART 06: Pipeline analysis 

PART 07: Market landscape 


Market overview 
Five forces analysis 


PART 08: Market segmentation by ROA 


Oral anticoagulants 
Injectable anticoagulants 
PART 09: Market segmentation by drug class 
Factor Xa inhibitors 
DTIs 
Heparin 
Vitamin K antagonists 


PART 10: Market segmentation by application 


DVT 
PE 
AF 
Others 


PART 11: Geographical segmentation 


Global anticoagulant market in Americas 
Anticoagulant market in EMEA 
Anticoagulant market in APAC 


PART 12: Market drivers 


Increasing demand for NOACs 
Growing prevalence of coagulation disorders 
Increase in hip and knee surgeries 


PART 13: Impact of drivers 

PART 14: Market challenges 


Increasing cost of NOACs 
Lack of antidotes in the market for NOACs 
Patent expiry: a threat to market 


PART 15: Impact of drivers and challenges 

PART 16: Market trends 


Strategic alliance 
Increasing focus toward emerging economies 
Patient assistance programs 


PART 17: Vendor landscape 


Competitive scenario 
Other prominent vendors 


PART 18: Key vendor analysis 


Bayer HealthCare 
Boehringer Ingelheim 
Bristol-Myers Squibb 
Daiichi Sankyo 
Johnson & Johnson 
Sanofi 


PART 19: Appendix 


List of abbreviations 


PART 20: Explore Technavio 
List of Exhibits

Exhibit 01: Product offerings 

Exhibit 02: Process of blood coagulation 

Exhibit 03: Mechanism of action (MoA) of anticoagulant 

Exhibit 04: Key customer segments of global anticoagulant market 

Exhibit 05: Pipeline analysis 2016 

Exhibit 06: Key pipeline molecules 

Exhibit 07: Global anticoagulant market overview 

Exhibit 08: Global anticoagulant market 2016-2021 ($ billions) 

Exhibit 09: Five forces analysis 

Exhibit 10: Segmentation of anticoagulant market based on ROA 

Exhibit 11: Market share of anticoagulant based on ROA 2016 

Exhibit 12: Types of heparin 

Exhibit 13: Segmentation of anticoagulant market based on drug class 

Exhibit 14: Market share of anticoagulant based on drug class 2016 

Exhibit 15: Types of factor Xa inhibitors based on MOA 

Exhibit 16: Factor Xa inhibitors in global anticoagulant market 2016-2021 ($ billions) 

Exhibit 17: Types of DTIs based on MOA 

Exhibit 18: DTIs in global anticoagulant market 2016-2021 ($ billions) 

Exhibit 19: Global heparin market 2016-2021 ($ billions) 

Exhibit 20: Global vitamin K antagonists market in 2016-2021 ($ billions) 

Exhibit 21: Market segmentation by application 

Exhibit 22: Market segmentation of anticoagulant based on application 

Exhibit 23: Anticoagulant market in Americas 2016-2021 ($ billions) 

Exhibit 24: Anticoagulant market in EMEA 2016-2021 ($ billions) 

Exhibit 25: Anticoagulant market in APAC 2016-2021 ($ billions) 

Exhibit 26: Impact of drivers 

Exhibit 27: Patents to expire over forecast period 

Exhibit 28: Impact of drivers and challenges 

Exhibit 29: Competitive structure analysis of global anticoagulant market 2016 

Exhibit 30: Competitive analysis of global anticoagulant market 

Exhibit 31: Market share analysis 2016 

Exhibit 32: Competitive landscape analysis 2016 

Exhibit 33: Bayer HealthCare: Key highlights 

Exhibit 34: Bayer HealthCare: Strength assessment 

Exhibit 35: Bayer HealthCare: Strategy assessment 

Exhibit 36: Bayer HealthCare: Opportunity assessment 

Exhibit 37: Bayer HealthCare: YoY revenue and growth rate of XARELTO 2013-2015 ($ billions) 

Exhibit 38: Boehringer Ingelheim: Key highlights 

Exhibit 39: Boehringer Ingelheim: Strength assessment 

Exhibit 40: Boehringer Ingelheim: Strategy assessment 

Exhibit 41: Boehringer Ingelheim: Opportunity assessment 

Exhibit 42: Boehringer Ingelheim: YoY revenue and growth rate of PRADAXA (global) 2013-2015 ($ billions) 

Exhibit 43: Bristol-Myers Squibb: Highlights 

Exhibit 44: Bristol-Myers Squibb: Strength assessment 

Exhibit 45: Bristol-Myers Squibb: Strategy assessment 

Exhibit 46: Bristol-Myers Squibb: Opportunity assessment 

Exhibit 47: Bristol-Myers Squibb: YoY revenue and growth rate of ELIQUIS (global) 2013-2015 ($ millions) 

Exhibit 48: Bristol-Myers Squibb: Geographic segmentation of ELIQUIS 2015 

Exhibit 49: Daiichi Sankyo: Key highlights 

Exhibit 50: Daiichi Sankyo: Strength assessment 

Exhibit 51: Daiichi Sankyo: Strategy assessment 

Exhibit 52: Daiichi Sankyo: Opportunity assessment 

Exhibit 53: Johnson & Johnson: Strength assessment 

Exhibit 54: Johnson & Johnson: Strategy assessment 

Exhibit 55: Johnson & Johnson: Opportunity assessment 

Exhibit 56: Sanofi: Key highlights 

Exhibit 57: Sanofi: Strength assessment 

Exhibit 58: Sanofi: Strategy assessment 

Exhibit 59: Sanofi: Opportunity assessment 

Exhibit 60: Sanofi: YoY revenue and growth rate of LOVENOX (global) 2013-2015 ($ billions) 

Exhibit 61: Sanofi: Geographical segmentation of LOVENOX 2016  

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $3500
USD $4500
USD $5000
Offer

Why Us

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.